2016-2018

December 28, 2018

參加2019 人類類澱粉蛋白影像會議 (Human Amyloid Imaging Conference)

新旭生技將會於2019年1月份在美國邁阿密出席Human Amyloid Imaging (HAI) 高峰會,並將會在大會中發表Tau蛋白正電子放射斷層攝影 (PET) 示蹤劑APN-1607 (PM-PBB3) 的最新臨床試驗成果。我們將會與我們的合作夥伴共發表10個演講。

December 25, 2018

新旭生技授權新基公司(Celgene)Tau蛋白正電子放射斷層攝影(PET)示蹤劑 [18F]-APN-1607

新旭生技與新基公司(Celgene Corporation)簽訂非專屬授權協議。該協議授權新基公司使用其開發中的新型Tau蛋白正電子放射斷層攝影(PET)示蹤劑,[18F]-APN-1607,於新基公司之全球臨床實驗中,以協助進行臨床收案和藥效評估。  

October 12, 2018

Emerging Company Profile - APRINOIA TACKLES TAU

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

September 01, 2018

APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference

APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.

January 16, 2018

APRINOIA Closed US$11.1 Million Series B Financing

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.

December 15, 2017

APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation

APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.

December 15, 2017

APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting

APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.

December 15, 2017

APRNIOIA Will Participate 2018 Human Amyloid Imaging Conference

APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.

December 12, 2016

參加2017 阿茲海默症及帕金森氏症國際研討會

新旭生技將在2017年三月於維也納舉行的第 13 屆阿茲海默症及帕金森氏症國際研討會中,發表其最新的 Tau 蛋白正子攝影顯像劑 APN-1607 (PM-PBB3) 首次進入人體的試驗結果。

December 12, 2016

參加2017 人類類澱粉蛋白影像會議

新旭生技將在2017年一月於邁阿密舉行的人類類澱粉蛋白影像會議 ( HAI ) 中,發表其最新的Tau 蛋白正子攝影顯像劑 APN-1607 (PM-PBB3) 首次進入人體的人體試驗結果。

December 05, 2016

主辦2016 神經疾病產學交流研討會

新旭生技非常榮幸於 2016 年 12 月 5 日與生物技術發展中心(DCB)和中央研究院一起主辦2016神經疾病產學交流研討會。

November 20, 2016

美國FDA核准新旭生技第二代PET示蹤劑進行人體試驗

新旭生技研發之第二代正子影像掃描(PET)示蹤劑於 2016 年 11 月 22 日獲得FDA核准在美國進行人體試驗(IND)。